TIDMTRX

RNS Number : 0705Y

Tissue Regenix Group PLC

01 December 2017

Tissue Regenix Group plc

Directorate Change

Leeds, 01 December 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company, announces that the Board has accepted the resignation of Paul Devlin, CFO. The Board will commence a process to appoint a successor.

Steve Couldwell, CEO, Tissue Regenix Group commented: "Paul played a significant role throughout the fundraise and acquisition process, we wish him every success in the future."

Current trading remains in line with Board expectations.

For more Information:

 
 Tissue Regenix Group plc                   Tel: 0330 
  Steve Couldwell CEO                        430 3073 
  Caitlin Pearson Head of Communications     / 07920272441 
----------------------------------------  ---------------- 
 Jefferies International Ltd               Tel: 020 
  Simon Hardy / Christopher Binks           7029 8000 
----------------------------------------  ---------------- 
 FTI Consulting                            Tel: 0203 
  Brett Pollard / Mo Noonan/ Rob Winder     727 1000 
========================================  ================

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds, UK. The company's patented decellularisation ('dCELL(R) ') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', January 2016 saw the establishment of joint venture GBM-V, a multi- tissue bank based in Rostock, Germany.

In August 2017 Tissue Regenix acquired CellRight Technologies(R) , a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopedic, foot & ankle, dental, and sports medicine surgical procedures.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAWGGRAGUPMPPU

(END) Dow Jones Newswires

December 01, 2017 02:01 ET (07:01 GMT)

Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Tissue Regenix Charts.
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Tissue Regenix Charts.